Table 2. Stratification analysis for the association between LINC00673 rs11655237 C>T polymorphism and neuroblastoma susceptibility for combined subjects.
| Variables | rs11655237 (cases/controls) | Crude OR | P | Adjusted OR1 | P1 | |
|---|---|---|---|---|---|---|
| CC | CT/TT | (95% CI) | (95% CI) | |||
| Age, months | ||||||
| ≤18 | 72/194 | 53/111 | 1.29 (0.84–1.97) | 0.245 | 1.29 (0.84–1.97) | 0.246 |
| >18 | 146/311 | 120/196 | 1.30 (0.97–1.76) | 0.083 | 1.30 (0.96–1.76) | 0.085 |
| Gender | ||||||
| Female | 89/210 | 79/132 | 1.41 (0.97–2.05) | 0.070 | 1.41 (0.97–2.05) | 0.071 |
| Male | 129/295 | 94/175 | 1.23 (0.89–1.70) | 0.215 | 1.23 (0.89–1.70) | 0.216 |
| Site of origin | ||||||
| Adrenal gland | 80/505 | 73/307 | 1.50 (1.06–2.13) | 0.022 | 1.51 (1.06–2.14) | 0.021 |
| Retroperitoneal | 49/505 | 36/307 | 1.21 (0.77–1.90) | 0.413 | 1.21 (0.77–1.91) | 0.402 |
| Mediastinum | 65/505 | 44/307 | 1.11 (0.74–1.68) | 0.606 | 1.11 (0.74–1.67) | 0.618 |
| Others | 22/505 | 14/307 | 1.05 (0.53–2.08) | 0.896 | 1.04 (0.53–2.07) | 0.904 |
| Clinical stages | ||||||
| I + II + 4s | 93/505 | 69/307 | 1.22 (0.87–1.72) | 0.254 | 1.21 (0.86–1.70) | 0.278 |
| III + IV | 115/505 | 95/307 | 1.36 (1.00–1.85) | 0.050 | 1.35 (1.00–1.84) | 0.054 |
| III | 43/505 | 25/307 | 0.96 (0.57–1.60) | 0.865 | 0.95 (0.57–1.59) | 0.854 |
| IV | 72/505 | 70/307 | 1.60 (1.12–2.29) | 0.010 | 1.60 (1.12–2.30) | 0.011 |
1
Adjusted for age and gender. Results shown in bold if 95% CI excluded 1 or P<0.05.